<p>随着欧洲市场显著回暖，STOXX 欧洲 600 指数在改善的地缘政治条件下上涨超过 3%，投资者正密切关注小型股领域的机会。在这种谨慎乐观的环境中，识别出具有强大基本面和潜在内部信心的股票，对于应对不断变化的市场格局至关重要。</p>
<h3>欧洲十大被低估的小型股及内部买入</h3>
<p>点击此处查看我们筛选出的 79 只被低估的欧洲小型股的完整列表。</p>
<p>让我们更详细地看看我们从筛选公司中挑选的几只股票。</p>
<h2>Gubra (CPSE:GUBRA)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Gubra 是一家专注于合同研究组织（CRO）服务和生物技术的公司，主要致力于开发代谢疾病的治疗，市值为 19.6 亿丹麦克朗。</p>
<p><strong>运营：</strong> 该公司主要通过其生物技术部门产生收入，该部门的增长速度显著超过 CRO 部门。最近一段时间，毛利率呈上升趋势，到 2025 年 12 月达到 96.96%。运营费用主要由研发和一般管理费用驱动。</p>
<p><strong>市盈率：</strong> 3.4 倍</p>
<p>Gubra 是一家生物技术公司，最近报告了 2025 年令人印象深刻的财务业绩，销售额从前一年的 2.6574 亿丹麦克朗飙升至 26 亿丹麦克朗，净收入达到 17 亿丹麦克朗，而之前则出现亏损。然而，预计未来三年每年的收益将平均下降 37%。该公司推出了 Gubra Ventures，以促进生物技术创新，同时其针对 GUB-UCN2 的临床试验申请旨在通过创新疗法解决与肥胖相关的问题。尽管外部借款风险较高，但内部信心在最近几个月的股票购买中得以体现，表明该小型股的战略举措和增长前景可能被市场认可。</p>
<ul>
<li>点击此处访问我们的完整估值分析报告，以了解 Gubra 的动态。</li>
<li>通过访问我们的历史业绩报告，评估 Gubra 的历史表现。</li>
</ul>
<h2>CellaVision (OM:CEVI)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> CellaVision 是一家瑞典公司，专注于医学显微镜的数字解决方案，主要聚焦于血液学，市值约为 75 亿瑞典克朗。</p>
<p><strong>运营：</strong> CellaVision 主要通过销售产生收入，最近的数据显示收入为 7.5897 亿瑞典克朗。公司的毛利率波动较大，最近记录为 68.50%。运营费用包括对销售和市场营销以及研发的重大投入。</p>
<p><strong>市盈率：</strong> 24.9 倍</p>
<p>CellaVision 作为数字细胞形态学行业的参与者，最近在 EMEA 推出了其骨髓抽吸应用，增强了对血液疾病的诊断能力。该应用的 CE 标志强调其符合欧盟安全标准。在财务方面，CellaVision 的销售额从前一年的 7.23 亿瑞典克朗上升至 2025 年的 7.59 亿瑞典克朗，净收入增加至 1.53 亿瑞典克朗。内部信心显而易见，Christer Fahraeus 今年收购了价值约 1569 万美元的股份。</p>
<ul>
<li>通过阅读我们的估值报告，深入了解 CellaVision 的表现。</li>
<li>查看我们的历史业绩报告，以获取 CellaVision 过去表现的见解。</li>
</ul>
<h2>Karnov Group (OM:KAR)</h2>
<p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Karnov Group 是一家提供法律和税务信息服务的公司，主要在北欧地区运营，市值为 42.8 亿瑞典克朗。</p>
<p><strong>运营：</strong> 该公司主要从北区和南区产生收入，最近的数据显示分别为 13.2 亿瑞典克朗。观察期间，其毛利率波动较大，过去曾达到 52.99%，但最近记录为 43.65%。运营费用波动显著，影响了净收入的波动，净收入在一段时间内从负值转为正值。</p>
<p><strong>市盈率：</strong> 7.6 倍</p>
<p>Karnov Group 作为欧洲市场的参与者，正在积极重塑其财务格局。最近，他们宣布将其股票回购计划增加至 7.5 亿瑞典克朗，计划于 2026 年 3 月 25 日实施。此举旨在优化资本结构并提升股东价值。尽管预计未来三年每年收益将下降近 30%，但内部信心通过显著的股票回购得以体现。该公司在截至 2025 年 12 月的完整年度中报告净收入为 9.7 亿瑞典克朗，扭转了之前的亏损。</p>
<ul>
<li>通过我们的综合估值报告深入了解 Karnov Group。</li>
<li>通过我们的详细历史业绩报告评估 Karnov Group 的过去表现。</li>
</ul>
<h2>利用机会</h2>
<ul>
<li>深入了解我们识别的 79 只被低估的欧洲小型股及内部买入。</li>
<li>这些公司是否是您投资策略的一部分？使用 Simply Wall St 将您的持股整合到一个投资组合中，并利用我们的综合分析工具获取见解。</li>
<li>使用免费的 Simply Wall St 应用程序，提供全球每个股票市场的详细见解，投资更聪明。</li>
</ul>
<h2>寻找其他投资？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型股公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，获得分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

ABCL

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

欧洲机会 IPOX ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

<p>随着欧洲市场的上涨，投资者正关注那些被低估的小型股以及内部人士的买入情况。值得注意的公司包括 Gubra，这是一家市值为 19.6 亿丹麦克朗的生物科技公司，虽然报告了显著的收入增长，但预计盈利将下降。CellaVision 专注于医学显微镜，显示出强劲的销售和内部人士的信心，最近进行了股票购买。Karnov Group 提供法律信息服务，尽管预计盈利将下降，但其股票回购计划已增加至 7.5 亿瑞典克朗。这些公司反映了在不断变化的市场环境中潜在的投资机会</p>

<p>As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing over 3% amid improved geopolitical conditions, investors are keenly observing the small-cap segment for opportunities. In this environment of cautious optimism, identifying stocks that demonstrate strong fundamentals and potential insider confidence can be crucial in navigating the evolving market landscape.</p>
<div class="lb-trans"><p>随着欧洲市场显著回暖，STOXX 欧洲 600 指数在改善的地缘政治条件下上涨超过 3%，投资者正密切关注小型股领域的机会。在这种谨慎乐观的环境中，识别出具有强大基本面和潜在内部信心的股票，对于应对不断变化的市场格局至关重要。</p>
</div><h3>Top 10 Undervalued Small Caps With Insider Buying In Europe</h3>
<div class="lb-trans"><h3>欧洲十大被低估的小型股及内部买入</h3>
</div><p>Click here to see the full list of 79 stocks from our Undervalued European Small Caps With Insider Buying screener.</p>
<div class="lb-trans"><p>点击此处查看我们筛选出的 79 只被低估的欧洲小型股的完整列表。</p>
</div><p>Let's take a closer look at a couple of our picks from the screened companies.</p>
<div class="lb-trans"><p>让我们更详细地看看我们从筛选公司中挑选的几只股票。</p>
</div><h2>Gubra (CPSE:GUBRA)</h2>
<div class="lb-trans"><h2>Gubra (CPSE:GUBRA)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Gubra is a company that specializes in contract research organization (CRO) services and biotechnology, with a focus on developing treatments for metabolic diseases, and has a market cap of DKK 1.96 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Gubra 是一家专注于合同研究组织（CRO）服务和生物技术的公司，主要致力于开发代谢疾病的治疗，市值为 19.6 亿丹麦克朗。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Biotech segment, which significantly outpaces the CRO segment. Over recent periods, the gross profit margin has shown an upward trend, reaching 96.96% by December 2025. Operating expenses are largely driven by R&amp;D and General &amp; Administrative costs.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要通过其生物技术部门产生收入，该部门的增长速度显著超过 CRO 部门。最近一段时间，毛利率呈上升趋势，到 2025 年 12 月达到 96.96%。运营费用主要由研发和一般管理费用驱动。</p>
</div><p><strong>PE:</strong> 3.4x</p>
<div class="lb-trans"><p><strong>市盈率：</strong> 3.4 倍</p>
</div><p>Gubra, a biotechnology company, has recently reported impressive financial results for 2025 with sales soaring to DKK 2.6 billion from DKK 265.74 million the previous year and net income reaching DKK 1.7 billion compared to a loss previously. However, earnings are expected to decline by an average of 37% annually over the next three years. The company has launched Gubra Ventures to foster biotech innovation while its clinical trial application for GUB-UCN2 aims at addressing obesity-related issues through innovative therapies. Despite high external borrowing risks, insider confidence is reflected in share purchases over recent months, indicating potential value recognition within this small-cap stock's strategic initiatives and growth prospects.</p>
<div class="lb-trans"><p>Gubra 是一家生物技术公司，最近报告了 2025 年令人印象深刻的财务业绩，销售额从前一年的 2.6574 亿丹麦克朗飙升至 26 亿丹麦克朗，净收入达到 17 亿丹麦克朗，而之前则出现亏损。然而，预计未来三年每年的收益将平均下降 37%。该公司推出了 Gubra Ventures，以促进生物技术创新，同时其针对 GUB-UCN2 的临床试验申请旨在通过创新疗法解决与肥胖相关的问题。尽管外部借款风险较高，但内部信心在最近几个月的股票购买中得以体现，表明该小型股的战略举措和增长前景可能被市场认可。</p>
</div><ul>
<li>Click here and access our complete valuation analysis report to understand the dynamics of Gubra.</li>
<li>Evaluate Gubra's historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此处访问我们的完整估值分析报告，以了解 Gubra 的动态。</li>
<li>通过访问我们的历史业绩报告，评估 Gubra 的历史表现。</li>
</ul>
</div><h2>CellaVision (OM:CEVI)</h2>
<div class="lb-trans"><h2>CellaVision (OM:CEVI)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> CellaVision is a Swedish company specializing in digital solutions for medical microscopy, primarily focusing on hematology, with a market capitalization of approximately SEK 7.50 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CellaVision 是一家瑞典公司，专注于医学显微镜的数字解决方案，主要聚焦于血液学，市值约为 75 亿瑞典克朗。</p>
</div><p><strong>Operations:</strong> CellaVision generates revenue primarily through its sales, with recent figures showing SEK 758.97 million in revenue. The company's gross profit margin has shown fluctuations, recently recorded at 68.50%. Operating expenses include significant allocations toward sales and marketing, as well as research and development efforts.</p>
<div class="lb-trans"><p><strong>运营：</strong> CellaVision 主要通过销售产生收入，最近的数据显示收入为 7.5897 亿瑞典克朗。公司的毛利率波动较大，最近记录为 68.50%。运营费用包括对销售和市场营销以及研发的重大投入。</p>
</div><p><strong>PE:</strong> 24.9x</p>
<div class="lb-trans"><p><strong>市盈率：</strong> 24.9 倍</p>
</div><p>CellaVision, a player in the digital cell morphology industry, recently launched its Bone Marrow Aspirate Application across EMEA, enhancing diagnostic capabilities for blood diseases. The application’s CE marking underlines its compliance with EU safety standards. Financially, CellaVision's sales rose to SEK 759 million in 2025 from SEK 723 million the previous year, while net income increased to SEK 153 million. Insider confidence is evident as Christer Fahraeus acquired shares worth approximately US$15.69 million this year.</p>
<div class="lb-trans"><p>CellaVision 作为数字细胞形态学行业的参与者，最近在 EMEA 推出了其骨髓抽吸应用，增强了对血液疾病的诊断能力。该应用的 CE 标志强调其符合欧盟安全标准。在财务方面，CellaVision 的销售额从前一年的 7.23 亿瑞典克朗上升至 2025 年的 7.59 亿瑞典克朗，净收入增加至 1.53 亿瑞典克朗。内部信心显而易见，Christer Fahraeus 今年收购了价值约 1569 万美元的股份。</p>
</div><ul>
<li>Get an in-depth perspective on CellaVision's performance by reading our valuation report here.</li>
<li>Review our historical performance report to gain insights into CellaVision's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过阅读我们的估值报告，深入了解 CellaVision 的表现。</li>
<li>查看我们的历史业绩报告，以获取 CellaVision 过去表现的见解。</li>
</ul>
</div><h2>Karnov Group (OM:KAR)</h2>
<div class="lb-trans"><h2>Karnov Group (OM:KAR)</h2>
</div><p><strong>Simply Wall St Value Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 价值评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Karnov Group is a provider of legal and tax information services, with operations primarily in the Nordic region and a market capitalization of SEK 4.28 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Karnov Group 是一家提供法律和税务信息服务的公司，主要在北欧地区运营，市值为 42.8 亿瑞典克朗。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from Region North and Region South, with recent figures indicating SEK 1.32 billion and SEK 1.32 billion respectively. Over the observed periods, its gross profit margin has shown variability, reaching as high as 52.99% in the past but most recently recorded at 43.65%. Operating expenses have fluctuated significantly, impacting net income margins which have varied widely from negative to positive values over time.</p>
<div class="lb-trans"><p><strong>运营：</strong> 该公司主要从北区和南区产生收入，最近的数据显示分别为 13.2 亿瑞典克朗。观察期间，其毛利率波动较大，过去曾达到 52.99%，但最近记录为 43.65%。运营费用波动显著，影响了净收入的波动，净收入在一段时间内从负值转为正值。</p>
</div><p><strong>PE:</strong> 7.6x</p>
<div class="lb-trans"><p><strong>市盈率：</strong> 7.6 倍</p>
</div><p>Karnov Group, a player in the European market, has been actively reshaping its financial landscape. Recently, they announced an increase in their equity buyback plan to SEK 750 million as of March 25, 2026. This move aims to optimize capital structure and enhance shareholder value. Despite a forecasted earnings decline of nearly 30% annually over the next three years, insider confidence remains evident through significant share repurchases. The company posted a net income of SEK 970 million for the full year ending December 2025, reversing from a previous loss.</p>
<div class="lb-trans"><p>Karnov Group 作为欧洲市场的参与者，正在积极重塑其财务格局。最近，他们宣布将其股票回购计划增加至 7.5 亿瑞典克朗，计划于 2026 年 3 月 25 日实施。此举旨在优化资本结构并提升股东价值。尽管预计未来三年每年收益将下降近 30%，但内部信心通过显著的股票回购得以体现。该公司在截至 2025 年 12 月的完整年度中报告净收入为 9.7 亿瑞典克朗，扭转了之前的亏损。</p>
</div><ul>
<li>Navigate through the intricacies of Karnov Group with our comprehensive valuation report here.</li>
<li>Assess Karnov Group's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合估值报告深入了解 Karnov Group。</li>
<li>通过我们的详细历史业绩报告评估 Karnov Group 的过去表现。</li>
</ul>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用机会</h2>
</div><ul>
<li>Dive into all 79 of the Undervalued European Small Caps With Insider Buying we have identified here.</li>
<li>Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.</li>
<li>Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.</li>
</ul>
<div class="lb-trans"><ul>
<li>深入了解我们识别的 79 只被低估的欧洲小型股及内部买入。</li>
<li>这些公司是否是您投资策略的一部分？使用 Simply Wall St 将您的持股整合到一个投资组合中，并利用我们的综合分析工具获取见解。</li>
<li>使用免费的 Simply Wall St 应用程序，提供全球每个股票市场的详细见解，投资更聪明。</li>
</ul>
</div><h2>Seeking Other Investments?</h2>
<div class="lb-trans"><h2>寻找其他投资？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型股公司。</li>
<li>用显示强劲增长潜力的公司充实您的投资组合，获得分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

Top European Undervalued Small Caps With Insider Action In April 2026

Simplywall

Abcellera Biologics

2026 年 4 月欧洲被低估的小盘股及内部人士的行动